Abbott’s acquisition of Exact Sciences deal marks a major move in the diagnostics sector as Abbott officially completed its $21 billion acquisition of Exact Sciences Corporation. The transaction closed on March 23, 2026, after Abbott’s wholly owned subsidiary, Badger Merger Sub I, Inc., merged with Exact Sciences. With this step, Exact Sciences has become a fully owned subsidiary of Abbott.
Under the agreement, each Exact Sciences shareholder received $105 in cash per share. The payment applies to all outstanding shares, subject to required tax withholdings. The transaction was funded through Abbott’s available cash and debt financing.
Exact Sciences Delisted from Nasdaq
Following the acquisition, Exact Sciences requested the delisting of its common stock from the Nasdaq Stock Market. Trading of the company’s shares stopped before the market opened on the day the deal closed. The company also plans to end its SEC reporting obligations now that it is privately held under Abbott.
As part of the process, all members of Exact Sciences’ board of directors and executive officers resigned at the effective time of the merger. The company’s certificate of incorporation and bylaws were amended to reflect its new ownership structure.
Shareholder Payout and Equity Conversion
The acquisition provides a significant cash payout for Exact Sciences shareholders. All outstanding stock options and equity awards were either converted into the right to receive the cash consideration or assumed by Abbott under revised terms. In addition, the company’s previously issued convertible notes were adjusted so they convert into cash based on the agreed $105 per-share price.
Strategic Expansion in Diagnostics
The Abbott’s acquisition of Exact Sciences deal strengthens Abbott’s position in the diagnostics and cancer screening market. Exact Sciences is known for its leading colorectal cancer screening tests and precision oncology products. By adding these offerings, Abbott expands its capabilities in early detection and personalised diagnostics.
This acquisition marks a major step for Abbott as it broadens its diagnostics portfolio and aims to support wider patient access to advanced cancer detection tools. With Exact Sciences now fully integrated, Abbott gains a stronger foothold in one of the fastest-growing areas of medical testing.
